Zurcher Kantonalbank Zurich Cantonalbank Has $156,000 Position in bluebird bio, Inc. (BLUE)

Zurcher Kantonalbank Zurich Cantonalbank lessened its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 14.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,481 shares of the biotechnology company’s stock after selling 242 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in bluebird bio were worth $156,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Teacher Retirement System of Texas grew its position in bluebird bio by 1.7% during the second quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock valued at $341,000 after buying an additional 53 shares during the period. Martingale Asset Management L P grew its position in bluebird bio by 0.6% during the first quarter. Martingale Asset Management L P now owns 17,008 shares of the biotechnology company’s stock valued at $1,547,000 after buying an additional 100 shares during the period. Prudential Financial Inc. grew its position in bluebird bio by 4.0% during the second quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock valued at $408,000 after buying an additional 150 shares during the period. Winfield Associates Inc. grew its position in bluebird bio by 6.1% during the second quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock valued at $296,000 after buying an additional 162 shares during the period. Finally, SG Americas Securities LLC grew its position in bluebird bio by 17.9% during the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 295 shares during the period.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://sportsperspectives.com/2017/09/19/zurcher-kantonalbank-zurich-cantonalbank-has-156000-position-in-bluebird-bio-inc-blue.html.

Several research firms recently commented on BLUE. BTIG Research restated a “buy” rating and set a $112.00 price target on shares of bluebird bio in a research report on Thursday, June 1st. Zacks Investment Research lowered shares of bluebird bio from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC restated a “buy” rating and set a $88.00 price target on shares of bluebird bio in a research report on Friday, August 11th. Finally, Maxim Group upgraded shares of bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $107.86.

bluebird bio, Inc. (NASDAQ:BLUE) opened at 133.05 on Tuesday. The stock’s market capitalization is $6.07 billion. The stock has a 50 day moving average of $107.34 and a 200 day moving average of $96.77. bluebird bio, Inc. has a 1-year low of $37.05 and a 1-year high of $136.85.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same period last year, the company earned ($1.59) earnings per share. The business’s revenue for the quarter was up 977.4% compared to the same quarter last year. On average, analysts expect that bluebird bio, Inc. will post ($6.84) earnings per share for the current year.

In related news, Director John Maraganore sold 18,868 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $131.21, for a total value of $2,475,670.28. Following the sale, the director now directly owns 24,711 shares of the company’s stock, valued at approximately $3,242,330.31. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Daniel Lynch sold 500 shares of the stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $120.00, for a total transaction of $60,000.00. Following the completion of the sale, the director now directly owns 3,300 shares in the company, valued at $396,000. The disclosure for this sale can be found here. Over the last three months, insiders sold 169,616 shares of company stock worth $19,884,020. 3.90% of the stock is owned by corporate insiders.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply